Stocks Health care PTGX
NASDAQ · Health careProtagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc brought in $551.7M of revenue over the twelve months to September 30, 2026, up 163.7% from a year earlier. Net income was $342.3M, a net margin of 62.0%. Operating cash flow minus capital spending left $56.1M of free cash flow in fiscal 2025. At September 30, 2026 it held $498.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Protagonist Therapeutics, Inc
- Net worth
- Protagonist Therapeutics, Inc has a market value (market cap) of $8.8B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $46M (-89.4% year on year), with a net loss of $130.1M. Over the 12 months to September 30, 2026: revenue $551.7M, net income $342.3M.
- Cash flow
- In fiscal 2025 operations brought in $57.7M of cash; after $1.6M of capital spending, free cash flow was $56.1M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Protagonist Therapeutics, Inc's next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Protagonist Therapeutics, Inc does
Protagonist Therapeutics, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PTGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $46M | -$130.1M | -$2.05 | $56.1M |
| 2024 | $434.4M | $275.2M | $4.23 | $182.8M |
| 2023 | $60M | -$79M | -$1.39 | -$70.8M |
| 2022 | $26.6M | -$127.4M | -$2.60 | -$108.9M |
| 2021 | $27.4M | -$125.6M | -$2.71 | -$109M |
| 2020 | $28.6M | -$66.2M | -$1.92 | -$73M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PTGX ranks in Health care
Latest SEC filings
What Protagonist Therapeutics, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 5,724% to $274.4M versus the same quarter last year; diluted EPS $3.07 versus -$0.62.
- November 5, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
- August 5, 2026Form S-8 POS filing S-8 POS
What is PTGX worth? A DCF from its reported cash flow
Insider trades
What the people running Protagonist Therapeutics, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $26.6M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 30, 2026 | Ali AsifChief Financial Officer | Exercised options | 9,229 | $359.7K |
| September 30, 2026 | Ali AsifChief Financial Officer | Exercised options | 28,438 | $666K |
| September 30, 2026 | Ali AsifChief Financial Officer | Exercised options | 15,650 | $300.3K |
| September 30, 2026 | Ali AsifChief Financial Officer | Exercised options | 5,312 | $64.6K |
| September 30, 2026 | Ali AsifChief Financial Officer | Soldpre-planned (10b5-1) | 12,595 | $1.8M |
| September 30, 2026 | Ali AsifChief Financial Officer | Soldpre-planned (10b5-1) | 46,034 | $6.5M |
| September 10, 2026 | Patel Dinesh V Ph DPresident and CEO, Director | Exercised options | 7,278 | $157.1K |
| September 10, 2026 | Patel Dinesh V Ph DPresident and CEO, Director | Soldpre-planned (10b5-1) | 7,278 | $1M |
Who owns PTGX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock, Inc.13G, passive | 15.2% | October 27, 2026 |
| Dapice Joshua J.13G, passive with 30 related filers | 9.99% | February 6, 2026 |
| Farallon Capital Management, L.L.C.13G, passive with 28 related filers | 9.99% | August 13, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 8.1% | February 17, 2026 |
| Vanguard Portfolio Management13G, passive | 5.53% | April 29, 2026 |
| Wellington Management Group LLP13G, passive with 2 related filers | 5.1% | February 10, 2026 |
| Vanguard Capital Management13G, passive | 5.09% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 343 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 10,307,837 | +528,468 |
| Farallon Capital Management, L.L.C. | 6,348,906 | 0 |
| Rtw Investments, LP | 5,061,175 | +2,122 |
| Vanguard Portfolio Management LLC | 3,629,298 | +148,087 |
| Wellington Management Group Llp | 3,416,781 | -182,863 |
| UBS Group AG | 3,399,221 | -1,778,575 |
| State Street Corp | 3,321,554 | +204,805 |
| Vanguard Capital Management LLC | 2,853,394 | +47,498 |
| Johnson & Johnson | 2,449,183 | 0 |
| Invesco Ltd. | 2,340,667 | +175,997 |
| Jupiter Topco LLC | 2,129,780 | new |
| Geode Capital Management, LLC | 1,741,209 | +71,838 |
| Woodline Partners LP | 1,414,173 | 0 |
| Bank of America Corp | 1,324,498 | +29,064 |
| Jennison Associates LLC | 1,151,681 | +79,670 |
| Perceptive Advisors LLC | 981,879 | -249,000 |
| ADAR1 Capital Management, LLC | 960,863 | -33,256 |
| Morgan Stanley | 905,992 | -112,230 |
| Alyeska Investment Group, L.P. | 889,298 | +296,101 |
| Hood River Capital Management LLC | 882,738 | +53,453 |
Insiders
8 insiders reported holding 763,101 shares in total, about $103.7M at the last price.
| Holder | Shares |
|---|---|
| Patel Dinesh V Ph DPresident and CEO, Director | 522,968 |
| Molina Arturo MdChief Medical Officer | 84,115 |
| Selick Harold EDirector | 60,845 |
| Ali AsifChief Financial Officer | 59,003 |
| Giraudo BryanDirector | 12,695 |
| Williams Lewis TDirector | 7,825 |
| Waddill William D.Director | 7,825 |
| O'Dowd Sarah ADirector | 7,825 |
Questions about PTGX
What does Protagonist Therapeutics, Inc do?
Protagonist Therapeutics, Inc is a company in the Health care sector, listed on NASDAQ as PTGX. Its shares trade on NASDAQ under the ticker PTGX.
What is Protagonist Therapeutics, Inc's net worth?
Protagonist Therapeutics, Inc has a market value (market cap) of $8.8B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Protagonist Therapeutics, Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $342.3M on revenue of $551.7M, a net margin of 62.0%.
How much revenue does Protagonist Therapeutics, Inc make?
Over the twelve months to September 30, 2026 Protagonist Therapeutics, Inc reported revenue of $551.7M. That is 163.7% more than a year earlier.
When did Protagonist Therapeutics, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is Protagonist Therapeutics, Inc's next earnings report?
Protagonist Therapeutics, Inc's next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PTGX with
Follow PTGX
Get an email when Protagonist Therapeutics, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Protagonist Therapeutics, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.